Results 51 to 60 of about 33,699 (271)

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study [PDF]

, 2014
Background Aclidinium/formoterol is a twice-daily (BID) fixed-dose combination (FDC) in development for chronic obstructive pulmonary disease (COPD).
Dave Singh, Paul W Jones, Eric D Bateman, Stephanie Korn, Cristina Serra, Eduard Molins, Cynthia Caracta, Esther Garcia Gil, Anne Leselbaum   +8 more
core   +1 more source

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events [PDF]

, 2010
Background An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews.
Aalbers, Aalbers, Altman, Barnes, Beach, Bleecker, Busse, Cates, Cates, Cates, Cates, Cates, Dahl, Ducharme, Ducharme, Ducharme, Giembycz, Higgins, Lasserson, Lipworth, Nelson, Ni Chroinin, Papi, Ringdal, Salpeter, Tamminen, Walters, Walters   +27 more
core   +2 more sources

Economic Evaluation Of Fluticasone Propionate/Formoterol Fumarate (Flutiform®) Vs Fluticasone/Salmeterol And Budesonide/Formoterol In Spain [PDF]

Value in Health, 2015
Introduction The aim of this economic evaluation was to estimate the cost-effectiveness of fluticasone propionate/formoterol (FP/FORM; Flutiform®) and compare it to those of fluticasone/salmeterol (FS) and budesonide/formoterol (BF) when used in the treatment of adult patients with moderate-to-severe asthma.
Martínez-Moragón, E, Delgado, J, Ojeda, P, Pérez del Llano, L, Antón, C, Martín, C, Collar, JM   +6 more
openaire   +2 more sources

Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial

Therapeutic Advances in Respiratory Disease, 2008
Formoterol fumarate is a long-acting β 2-agonist that is an effective bronchodilator for the maintenance management of patients with chronic obstructive pulmonary disease.
James F. Donohue, Nicola A. Hanania, Charles Fogarty, Sammy C. Campbell, Mike Rinehart, Kimberly Denis-Mize   +5 more
doaj   +1 more source

Effect of aclidinium bromide on exacerbations in patients with moderate to severe COPD: a pooled analysis of five Phase III, randomized, placebo-controlled studies [PDF]

, 2017
We investigated the effect of the long-acting muscarinic antagonist aclidinium bromide on chronic obstructive pulmonary disease (COPD) exacerbations by pooling data from five randomized, placebo-controlled,parallel-group Phase III studies of 3-6 months ...
Agustí García-Navarro, Àlvar, Chuecos, Ferran, Donaldson, Gavin, Garcia Gil, Esther, Lamarca, Rosa, Wedzicha, Jadwiga A.   +5 more
core   +1 more source

Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. [PDF]

, 2011
BACKGROUND: Interactions between spirometry and patient-reported outcomes in COPD are not well understood. This systematic review and study-level analysis investigated the relationship between changes in FEV1 and changes in health status with ...
Bourbeau, J, Capkun-Niggli, G, Cerulli, A, Jones, PW, Westwood, M, Worthy, G   +5 more
core   +2 more sources

Long-acting beta2-agonists for chronic obstructive pulmonary disease. [PDF]

, 2013
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a respiratory disease that causes progressive symptoms of breathlessness, cough and mucus build-up.
Aalbers, Allegra, Amgott, Anderson, Appleton, Arievich, Bateman, Bateman, Baumgartner, Beeh, Berger, Bleecker, Bleecker, Bogdan, Bogdan, Boyd, Boyd, Briggs, British Medical Association and the Royal Pharmaceutical Society of Great Britain, Brusasco, Brusasco, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Campbell, Campbell, Celli, Celli, Celli, Celli, Celli, Celli, Celli, Celli, Chapman, Chapman, Cheyne, Chong, Chong, Corhay, Dahl, Dahl, Dahl, Dahl, Dahl, Dahl, Dal Negro, Dal Negro, Doherty, Doherty, Doherty, Doherty, Donohue, Donohue, Donohue, Donohue, Effing, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Geake, Greefhorst, Greefhorst, Greefhorst, Gross, Hanania, Hanania, Hanrahan, Hanrahan, Hanrahan, Hanrahan, Hanrahan, Higgins, Hogan, Horstman, Hunjan, Hunjan, Hutchinson, Jenkins, Jenkins, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Karner, Karner, Karner, Karner, Karner, Keene, Kerwin, Kerwin, Khamis, Kliber, Kornmann, Kornmann, Kristufek, Kristufek, Kristufek, Lacasse, Laties, Littner, Lofdahl, Lofdahl, Lofdahl, Lofdahl, Mahler, Mahler, Mahler, Mahler, Matiz-Bueno, Matiz-Bueno, McDonough, McGarvey, Meer, Nannini, Nannini, Nannini, Nelson, Nelson, Nelson, Nelson, Nitschmann, Noord, Noord, Puhan, Qaseem, Rennard, Rennard, Rennard, Rennard, Rodrigo, Rossi, Rutten-van Molken, Rutten-van Mölken, Sacchetta, Sciurba, Song, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Stahl, Steffensen, Steffensen, Stockley, Stockley, Szafranski, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Vestbo, Vestbo, Vestbo, Vestbo, Vogelmeier, Vogelmeier, Wadbo, Wang, Watkins, Welsh, Yang   +198 more
core   +1 more source

NMR characterisation of dynamics in solvates and desolvates of formoterol fumarate [PDF]

Physical Chemistry Chemical Physics, 2013
Solid-state NMR is used to characterise dynamics in the ethanol solvate of the pharmaceutical material formoterol fumarate and its associated desolvate. Jump rates and activation barriers for dynamic processes such as phenyl ring rotation and methyl group rotational diffusion are derived from 1D-EXSY and (13)C spin-lattice relaxation times respectively.
Apperley, D., Markwell, A.F., Frantsuzov, I., Ilott, A.J., Harris, R.K., Hodgkinson, P.   +5 more
openaire   +3 more sources

Faster Onset of Bronchodilation with Formoterol than with Salmeterol in Patients with Stable, Moderate-Severe Copd: Results of a Randomized, Double-Blind Clinical Study

Canadian Respiratory Journal, 2002
OBJECTIVES: To compare the onset and magnitude of bronchodilation after dry powder inhalations of formoterol fumarate (Foradil Aerolizer) versus salmeterol xinofoate (Serevent Diskus) with respect to normalized (*) forced expiratory volume in 1 s area ...
John Kottakis, Giovanni Della Cioppa, Jacques Creemers, Louis Greefhorst, Violette Leclerc, Riccardo Pistelli, Tim Overend, Denise Till, Günter Rapatz, Vincent LeGros, Demosthenes Bouros, Nikolaos Siafakas   +11 more
doaj   +1 more source

Nanoparticles in the treatment of chronic lung diseases [PDF]

, 2019
Nanoparticles, although considered a topic of modern medicine, actually have an interesting history. Currently, advances in nanomedicine hold great promise as drug carrier systems for sustained release and targeted delivery of diverse therapeutic agents.
Alexescu, Teodora G, Cosnarovici, Maria, Negrean, Vasile, Orasan, Olga H, Para, Ioana, Perne, Mirela G, Popovici, Ionela, Ruta, Victoria M, Tarmure, Simina, Todea, Doina A   +9 more
core   +2 more sources